Abstract
The results of these studies suggested that the growth hormone might play a role in the management of visceral fat accumulation associated with HIV. Analysis of the treatment effect sizes in the published studies show that the effects of various doses of rhGH on trunk fat fit a dose-response characteristic.
Highlights
Nutritional alterations are common in HIV infection
Nutritional alterations in the preHAART era were characterized by disproportionate losses of lean body mass and skeletal muscle
At the time of publication of this review, growth hormone is FDA approved for the treatment of AIDS wasting and is not FDA approved for the treatment of HIV-associated lipodystrophy or related conditions
Summary
Nutritional alterations are common in HIV infection. The types of nutritional abnormalities encountered in clinical practice differ as a function of antiretroviral therapy. In addition growth hormone secretion, as measured by overnight sampling methods, is low in non-HIV infected patients[16] In such subjects, replacement therapy reduces visceral fat content. A second randomization, covering from 12-24 weeks, provided pilot information about possible long term strategies and included drug discontinuation from 4 mg/day, dose reduction from 4 mg to 2 mg/day and drug continuation at 2 mg/day, while subjects initially receiving placebo were given 4 mg/day After another 12 weeks in which all subjects received growth hormone, a third randomization was performed and subjects received either 1 mg or 2 mg per day of rhGH for an additional 6 months as an expanded trial of maintenance therapy.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
